Ding et al. verified that miR-204 inhibited the growth of prostatic adenocarcinoma cells, whereas it stimulated the growth of neuroendocrine-like prostate cancer cells via targeting XRN1, a dual regulator with variable abundance of proteins in these cells (80). Here, XRN1 is linked to prostate cancer.